Literature DB >> 30328622

Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs.

Peter J West1,2,3, Gerald W Saunders2, Peggy Billingsley2, Misty D Smith1,2,4, H Steve White5, Cameron S Metcalf1,2, Karen S Wilcox1,2,3.   

Abstract

OBJECTIVE: Approximately 30% of patients with epilepsy are refractory to existing antiseizure drugs (ASDs). Given that the properties of the central nervous systems of these patients are likely to be altered due to their epilepsy, tissues from rodents that have undergone epileptogenesis might provide a therapeutically relevant disease substrate for identifying compounds capable of attenuating pharmacoresistant seizures. To facilitate the development of such a model, this study describes the effects of classical glutamate receptor antagonists and 20 ASDs on recurrent epileptiform discharges (REDs) in brain slices derived from the kainate-induced status epilepticus model of temporal lobe epilepsy (KA-rats).
METHODS: Horizontal brain slices containing the medial entorhinal cortex (mEC) were prepared from KA-rats, and REDs were recorded from the superficial layers. 6-cyano-7-nitroquinoxaline-2,3-dione, (2R)-amino-5-phosphonovaleric acid, tetrodotoxin, or ASDs were bath applied for 20 minutes. Concentration-dependent effects and half maximal effective concentration values were determined for RED duration, frequency, and amplitude.
RESULTS: ASDs targeting sodium and potassium channels (carbamazepine, eslicarbazepine, ezogabine, lamotrigine, lacosamide, phenytoin, and rufinamide) attenuated REDs at concentrations near their average therapeutic plasma concentrations. γ-aminobutyric acid (GABA)ergic synaptic transmission-modulating ASDs (clobazam, midazolam, phenobarbital, stiripentol, tiagabine, and vigabatrin) attenuated REDs only at higher concentrations and, in some cases, prolonged RED durations. ASDs with other/mixed mechanisms of action (bumetanide, ethosuximide, felbamate, gabapentin, levetiracetam, topiramate, and valproate) and glutamate receptor antagonists weakly or incompletely inhibited RED frequency, increased RED duration, or had no significant effects. SIGNIFICANCE: Taken together, these data suggest that epileptiform activity recorded from the superficial layers of the mEC in slices obtained from KA-rats is differentially sensitive to existing ASDs. The different sensitivities of REDs to these ASDs may reflect persistent molecular, cellular, and/or network-level changes resulting from disease. These data are expected to serve as a foundation upon which future therapeutics may be differentiated and assessed for potentially translatable efficacy in patients with refractory epilepsy. Wiley Periodicals, Inc.
© 2018 International League Against Epilepsy.

Entities:  

Keywords:  antiepileptic drugs; brain slices; pharmacoresistance

Mesh:

Substances:

Year:  2018        PMID: 30328622      PMCID: PMC6215509          DOI: 10.1111/epi.14563

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  39 in total

1.  The impact of nonadherence to antiseizure drugs on seizure outcomes in an animal model of epilepsy.

Authors:  Kyle E Thomson; Avani C Modi; Tracy A Glauser; Joseph R Rausch; H Steve White
Journal:  Epilepsia       Date:  2017-04-12       Impact factor: 5.864

Review 2.  Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

3.  Characterization of spontaneous recurrent epileptiform discharges in hippocampal-entorhinal cortical slices prepared from chronic epileptic animals.

Authors:  Dawn S Carter; Laxmikant S Deshpande; Azhar Rafiq; Sompong Sombati; Robert J DeLorenzo
Journal:  Seizure       Date:  2010-12-18       Impact factor: 3.184

Review 4.  The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.

Authors:  Martin J Gunthorpe; Charles H Large; Raman Sankar
Journal:  Epilepsia       Date:  2012-01-05       Impact factor: 5.864

5.  Increased susceptibility to acetylcholine in the entorhinal cortex of pilocarpine-treated rats involves alterations in KCNQ channels.

Authors:  Anna Maslarova; Seda Salar; Ezequiel Lapilover; Alon Friedman; Rüdiger W Veh; Uwe Heinemann
Journal:  Neurobiol Dis       Date:  2013-04-11       Impact factor: 5.996

Review 6.  Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies.

Authors:  Wolfgang Löscher
Journal:  Epilepsy Res       Date:  2016-08-01       Impact factor: 3.045

7.  Acetylcholine-induced seizure-like activity and modified cholinergic gene expression in chronically epileptic rats.

Authors:  Gabriel Zimmerman; Marleisje Njunting; Sebastian Ivens; Else A Tolner; Elsa Tolner; Christoph J Behrens; Miriam Gross; Hermona Soreq; Uwe Heinemann; Alon Friedman
Journal:  Eur J Neurosci       Date:  2008-02       Impact factor: 3.386

8.  Reduced ictogenic potential of 4-aminopyridine in the perirhinal and entorhinal cortex of kainate-treated chronic epileptic rats.

Authors:  Robert K Zahn; Else A Tolner; Christian Derst; Clemens Gruber; Rüdiger W Veh; Uwe Heinemann
Journal:  Neurobiol Dis       Date:  2007-09-04       Impact factor: 5.996

Review 9.  Methodological standards for in vitro models of epilepsy and epileptic seizures. A TASK1-WG4 report of the AES/ILAE Translational Task Force of the ILAE.

Authors:  Joseph V Raimondo; Uwe Heinemann; Marco de Curtis; Howard P Goodkin; Chris G Dulla; Damir Janigro; Akio Ikeda; Chou-Ching K Lin; Premysl Jiruska; Aristea S Galanopoulou; Christophe Bernard
Journal:  Epilepsia       Date:  2017-11       Impact factor: 5.864

10.  Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electrographic bursting in the medial entorhinal cortex (mEC).

Authors:  Misty D Smith; Gerald W Saunders; Rasmus P Clausen; Bente Frølund; Povl Krogsgaard-Larsen; Orla M Larsson; Arne Schousboe; Karen S Wilcox; H Steve White
Journal:  Epilepsy Res       Date:  2008-02-08       Impact factor: 3.045

View more
  9 in total

1.  The Positive Allosteric Modulator of α2/3-Containing GABAA Receptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury.

Authors:  Jeffrey M Witkin; Guanguan Li; Lalit K Golani; Wenhui Xiong; Jodi L Smith; Xingjie Ping; Farjana Rashid; Rajwana Jahan; Rok Cerne; James M Cook; Xiaoming Jin
Journal:  J Pharmacol Exp Ther       Date:  2019-11-06       Impact factor: 4.030

2.  Stereospecific antiseizure activity in mouse and rat epilepsy models by a pyridinium inhibitor of TNFα/NFκB signaling.

Authors:  Bette S Pollard; Zhiwei Wen; Kenneth A Jacobson; John R Pollard
Journal:  Eur J Med Chem Rep       Date:  2022-06-08

3.  Discovery of the First Vitamin K Analogue as a Potential Treatment of Pharmacoresistant Seizures.

Authors:  Xiaoyang Li; Richard A Himes; Lyndsey C Prosser; Charleston F Christie; Emma Watt; Sharon F Edwards; Cameron S Metcalf; Peter J West; Karen S Wilcox; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-22       Impact factor: 7.446

Review 4.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

5.  Brivaracetam Modulates Short-Term Synaptic Activity and Low-Frequency Spontaneous Brain Activity by Delaying Synaptic Vesicle Recycling in Two Distinct Rodent Models of Epileptic Seizures.

Authors:  Hang Xing; Xiong Han; Sihan Xu; Zhongyu Sun; Shijun Yang
Journal:  J Mol Neurosci       Date:  2022-03-12       Impact factor: 3.444

6.  Sulfasalazine decreases mouse cortical hyperexcitability.

Authors:  Oscar Alcoreza; Bhanu P Tewari; Allison Bouslog; Andrew Savoia; Harald Sontheimer; Susan L Campbell
Journal:  Epilepsia       Date:  2019-06-18       Impact factor: 5.864

7.  Spontaneous recurrent seizures in an intra-amygdala kainate microinjection model of temporal lobe epilepsy are differentially sensitive to antiseizure drugs.

Authors:  Peter J West; Kyle Thomson; Peggy Billingsley; Timothy Pruess; Carlos Rueda; Gerald W Saunders; Misty D Smith; Cameron S Metcalf; Karen S Wilcox
Journal:  Exp Neurol       Date:  2021-12-17       Impact factor: 5.620

Review 8.  Factors not considered in the study of drug-resistant epilepsy: Drug-resistant epilepsy: Assessment of neuroinflammation.

Authors:  Patricia Campos-Bedolla; Iris Feria-Romero; Sandra Orozco-Suárez
Journal:  Epilepsia Open       Date:  2022-03-16

Review 9.  The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.

Authors:  Karen S Wilcox; Peter J West; Cameron S Metcalf
Journal:  Neuropharmacology       Date:  2019-11-30       Impact factor: 5.273

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.